A2 share price frenzy – but is the US formula market worth it?

A2 share price frenzy – but is the US formula market worth it?
The American dream may not be worth it for A2. (Image: Getty)
Jenny Ruth
Some investors believe accessing the US infant formula market would be a big deal for Fonterra and the A2 Milk Company, and trading in A2’s shares last week highlighted that fact.An Australian Financial Review (AFR) journalist got a little over her skis on Tuesday and published a story saying A2 could get US Food & Drug Administration (FDA) approval “as soon as this week”.Both Fonterra and A2 have been waiting for this approval since they applied in late May after the FDA made public it was looking to facilitate infant for...

More Primary Sector

Bell Potter boosts Santana target price 53.5%
Primary Sector

Bell Potter boosts Santana target price 53.5%

Aussie brokers increasingly like the look of a low-cost, high yield Otago gold play.

Pattrick Smellie 19 Apr 2024
Anna Palairet appointed Fonterra's chief operating officer
Primary Sector

Anna Palairet appointed Fonterra's chief operating officer

Having acted in the role since June last year, she replaces Fraser Whineray.

Riley Kennedy 19 Apr 2024